{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.8","upperLimit":"68.0","value":"44.75"},{"groupId":"OG001","lowerLimit":"36.1","upperLimit":"61.5","value":"44.05"},{"groupId":"OG002","lowerLimit":"22.8","upperLimit":"88.8","value":"52.00"},{"groupId":"OG003","lowerLimit":"31.4","upperLimit":"76.7","value":"45.25"},{"groupId":"OG004","lowerLimit":"12.9","upperLimit":"30.6","value":"22.30"},{"groupId":"OG005","lowerLimit":"29.1","upperLimit":"57.6","value":"45.80"},{"groupId":"OG006","lowerLimit":"11.0","upperLimit":"49.1","value":"30.10"},{"groupId":"OG007","lowerLimit":"37.2","upperLimit":"215.0","value":"54.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"16"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"12.2","upperLimit":"48.4","value":"22.60"},{"groupId":"OG006","lowerLimit":"17.5","upperLimit":"55.7","value":"32.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"30.5","upperLimit":"64.0","value":"46.00"},{"groupId":"OG004","lowerLimit":"16.7","upperLimit":"32.4","value":"27.10"},{"groupId":"OG005","lowerLimit":"26.8","upperLimit":"254.0","value":"44.50"},{"groupId":"OG006","lowerLimit":"14.6","upperLimit":"53.2","value":"26.20"},{"groupId":"OG007","lowerLimit":"45.7","upperLimit":"57.8","value":"51.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"WEEK 4 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.9","upperLimit":"83.6","value":"48.60"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"71.8","value":"44.30"},{"groupId":"OG002","lowerLimit":"26.5","upperLimit":"76.9","value":"36.45"},{"groupId":"OG003","lowerLimit":"25.9","upperLimit":"84.1","value":"42.50"},{"groupId":"OG004","lowerLimit":"19.1","upperLimit":"29.7","value":"26.30"},{"groupId":"OG005","lowerLimit":"18.2","upperLimit":"62.7","value":"31.70"},{"groupId":"OG006","lowerLimit":"12.1","upperLimit":"38.6","value":"27.40"},{"groupId":"OG007","lowerLimit":"37.0","upperLimit":"55.8","value":"38.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"WEEK 7 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"21.0","upperLimit":"32.6","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"37.0","upperLimit":"45.1","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 8"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"19.1","upperLimit":"19.1","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 11"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"31.9","upperLimit":"43.3","value":"38.00"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"81.8","upperLimit":"81.8","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"24.9","upperLimit":"33.2","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"28.7","upperLimit":"28.7","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG007","lowerLimit":"60.3","upperLimit":"60.3","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"WEEK 10 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"28.2","upperLimit":"28.2","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 10 DAY 8"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"33.3","upperLimit":"33.3","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG001","lowerLimit":"46.9","upperLimit":"46.9","value":"NA"},{"groupId":"OG002","lowerLimit":"31.1","upperLimit":"60.1","value":"43.30"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"70.8","upperLimit":"95.7","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG005","lowerLimit":"33.5","upperLimit":"43.5","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"27.9","upperLimit":"27.9","value":"NA"},{"groupId":"OG007","lowerLimit":"41.4","upperLimit":"62.3","value":"46.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"WEEK 13 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"37.0","upperLimit":"37.0","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 13 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}],"units":"Participants"}],"description":"Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 10 Day 8, Week 13 Day 1, Week 13 Day 8","title":"C-EOI for Belantamab Mafodotin ADC, Treatment B","type":"SECONDARY","unitOfMeasure":"ug/mL"}